MAF-Test® employs high quality, reliable and easy-to-use DNA probes for fluorescence in situ hybridization (FISH) for the determination of MAF gene amplification in early breast cancer tumors.
The MAF (16q23) / D16Z3 FISH probe (MAF-Test®) is intended for use in a non-automated semi-qualitative fluorescence in situ hybridization assay to detect amplification involving the MAF gene region at 16q23 in a dual-color assay on formalin fixed paraffin embedded breast cancer tissue sections. The centromere 16 specific centromere repeat probe (D16Z3) is included as control on hybridization efficiency.
The MAF (16q23) gene region FISH probe is direct-labeled with PlatinumBright™550 (red). The D16Z3 control FISH probe is direct-labeled with PlatinumBright495 (green).
MAF gene amplification in primary tumors has been associated with an increased risk of relapse, death, and metastasis, especially bone metastasis, in early-stage breast cancer patients (Paterson et al., 2021). MAF gene amplification may be considered as an adverse prognostic factor of the disease.
Increrased risk of bone and non-bone metastasis in MAF positive patients translates to reduced disease free and overall survival.